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The structural complexity of chromosome 1p centromeric region has been an obstacle for fine mapping of tumor suppressor
genes in this area. Loss of heterozygosity (LOH) on chromosome 1p is associated with the longer survival of oligodendroglioma
(OD) patients. To test the clinical relevance of 1p loss in glioblastomas (GBM) patients and identifiy the underlying tumor
suppressor locus, we constructed a somatic deletion map on chromosome 1p in 26 OG and 118 GBM. Deletion hotspots at 4
microsatellite markers located at 1p36.3, 1p36.1, 1p22 and 1p11 defined 10 distinct haplotypes that were related to patient
survival. We found that loss of 1p centromeric marker D1S2696 within NOTCH2 intron 12 was associated with favorable
prognosis in OD (P=0.0007) as well as in GBM (P=0.0175), while 19q loss, concomitant with 1p LOH in OD, had no influence on
GBM survival (P=0.918). Assessment of the intra-chromosomal ratio between NOTCH2 and its 1q21 pericentric duplication
N2N (N2/N2N-test) allowed delineation of a consistent centromeric breakpoint in OD that also contained a minimally lost area
in GBM. OD and GBM showed distinct deletion patterns that converged to the NOTCH2 gene in both glioma subtypes.
Moreover, the N2/N2N-test disclosed homozygous deletions of NOTCH2 in primary OD. The N2/N2N test distinguished OD from
GBM with a specificity of 100% and a sensitivity of 97%. Combined assessment of NOTCH2 genetic markers D1S2696 and N2/
N2N predicted 24-month survival with an accuracy (0.925) that is equivalent to histological classification combined with the
D1S2696 status (0.954) and higher than current genetic evaluation by 1p/19q LOH (0.762). Our data propose NOTCH2 as
a powerful new molecular test to detect prognostically favorable gliomas.
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INTRODUCTION
Histological classification and the WHO grading of glial brain
tumors represents the gold standard to estimate prognosis and
guide therapy [1,2]. Median survival time of glioma patients varies
considerably between gliomas of different histological type and
WHO grade, e.g. it is less than 12 months in GBM [3], 10 years in
OD grade II [4] and approximately 3–4 years in anaplastic OD
grade III [5]. However, histological classification of malignant
gliomas can be difficult, especially if only small amounts of
stereotactic biopsies are available [6]. Even within one histological
glioma subtype, the course of the disease can be highly variable,
depending of the genetic background of the tumor. For these
reasons, molecular markers are expected to improve diagnostic
and prognostic accuracy and guide therapy.
Genetically, OD differ from GBM by frequent loss of heterozy-
gosity (LOH) on the entire chromosome 1p, combined with LOH on
19q [7,8], which is a result from an unbalanced translocation
t(1;19)(q10;p10) [9,10]. This genetic alteration is associated with
favorable prognosis and response to radio- and chemotherapy in OD
grade III [11,12]. Candidate chromosome 1p brain tumor suppressor
genesproposed sofar,TP73 [13], RAD54 [6], CDKN2C/p18
INK4c [14]
and CHD5 [15], are located on distal 1p. In OD, recent deletion
mapping only disclosed a few non-overlapping partial deletions,
located on 1p34.2-tel [16]. Genetic mapping of subtelomeric regions
may, however, be obscured by random deletions in cancer cells [17].
Moreover, the reference sequence of human chromosome 1 only
recently unraveled the structural complexity of intrachromosomal
duplications, particularly at the centromeric region [18].
In contrast to OD, the significance of LOH on 1p as a
prognostic marker is not clear in malignant astrocytoma, although
a correlation had also been postulated for GBM [19]. We
therefore compared the deletion patterns on 1p in a large series of
OD and GBM, constructing genetic deletion maps of 1p to
determine distinct 1p haplotypes in relation to patient survival.
RESULTS
Favorable prognosis in gliomas is associated with
centromeric 1p LOH
We performed somatic deletion mapping in 26 primary OD and
118 GBM, using 43 polymorphic microsatellite markers on
chromosome 1. LOH on chromosome 1p was found in 81%
(21/26) of OD at all informative markers. In contrast, 69% GBM
(80/118) had retention on 1p and 31% displayed various deletion
patterns with hotspots at markers D1S2845, D1S507, D1S216 and
D1S2696. We grouped these deletion patterns into 10 different
haplotypes where haplotype H1 designates no deletion on 1p, H2–
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PLoS ONE | www.plosone.org 1 June 2007 | Issue 6 | e576Figure 1. Glioma patients with centromeric 1p allelic loss show better survival. (A) Deletion patterns on chromosome 1p in GBM and OD. Somatic
deletion mapping in 118 GBM and 26 OD WHO grades II and III was performed using 43 microsatellite markers. Four markers at deletion hotspots
(D1S2845 at 1p36.3, D1S507 at 1p36.1, D1S216 at 1p22 and D1S2696 at 1p11) were selected to define chromosome 1p haplotypes. In GBM, 10
haplotypes were grouped into tumors with centromeric (H8–H10), interstitial (H5–H7) and telomeric (H2–H4) deletion patterns. In OD, only
haplotypes H1 and H10 were observed. Chromosomal positions of 1p markers are shown on the left and areas of allelic loss are shown in grey. (B)
Kaplan-Meier cumulative survival curve of the haplotype groups.
doi:10.1371/journal.pone.0000576.g001
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(Figure 1A). GBM displayed the entire spectrum of haplotypes
H1–H10 whereas OD only harbored haplotypes H1 and H10
(Figure 1A). In OD, haplotype H10 significantly differed in
survival time compared to H1 (P=0.0007, Logrank Mantel-Cox,
Figure S1). Within haplotype H1, OD still had a more favorable
prognosis than GBM (OD H1 vs. GBM H1, P=0.0184). Overall,
survival time did not differ between GBM with and without 1p
loss (GBM H1 vs. GBM H2–H10, P=0.29). However, GBM
haplotypes H8–H10, defined by LOH at centromeric marker
D1S2696, had a better survival than GBM haplotypes H2–H7,
defined by D1S2696 retention (GBM H8–H10 vs. GBM H2–H7,
P=0.0163). Average age of patients with GBM haplotypes H8–
H10 (60.3 years) was similar to the average age of all GBM
patients regardless of haplotype (58.7 year), indicating that longer
survival of this subset of GBM is not related to patient age
(Table 1). Moreover, the variety of treatment regimens was
unlikely to significantly influence patient outcome (Table 2). GBM
haplotypes H2–H7 were further divided based on telomeric
marker D1S2845 status, those with retention (GBM H5–H7)
showing significantly poorer survival than those with LOH (GBM
H2–H4) (GBM H5–H7 vs. GBM H2–H4, P=0.0154). Thus,
GBM with 1p loss were subdivided into 3 categories defined by
telomeric (H2–H4, 47%), interstitial (H5–H7, 29%) and centro-
meric deletions (H8–H10, 24%). GBM with centromeric deletions
had the most favorable prognosis (GBM H8–H10 vs. H1,
P=0.0175) while GBM with interstitial deletions the worst
(GBM H5–H7 vs. H1, P=0.0187) and a lower age at diagnosis
(50.7). However, survival did not differ between GBM with the
prevalent telomeric deletions versus GBM with 1p retention (GBM
H2–H4 vs. H1, P=0.531, Logrank Mantel-Cox, Figure 1B).
Thus, this initial mapping on primary gliomas revealed a centro-
meric chromosome 1 area associated with better survival, and
another one, more distal, linked with poorer survival.
LOH on 19q is not associated with 1p loss in GBM
Since LOH of 1p and 19q are concomitant in OD [8], we
analyzed 19q status in all OD and GBM displaying 1p loss. As
expected [20], 100% (21/21) of OD with haplotype H10 had 19q
loss and significantly better prognosis (P=0.0038, Manova). In
contrast, only 47% of GBM with haplotypes H2–H10 displayed
concomitant 19q loss, which was randomly distributed among the
three 1p deletion categories, not correlating with survival
(P=0.918, Manova). These data suggest that only 1p loss rather
than 19q loss predict better survival in the subgroup of GBM
patients with 1p loss, distinct from OD patients that display co-
deletions of 1p and 19q. The centromeric marker D1S2696 was
indeed the best discriminator for longer survival in both GBM and
OD compared to more telomeric 1p and 19q markers (Figure 2).
Minimally lost areas in OD and GBM converge to
NOTCH2
GBM with haplotypes H8–H10 define a minimally lost area that
spans between markers D1S514 and 210WF10 and overlaps the
centromeric breakpoint cluster between markers D1S2696 and
210WF10 in OD with haplotype H10 (Figure 3B). Refinement of
deletion mapping in this area has so far been limited by pericentric
duplication of chromosome 1 [18]. This duplicates the 5’ part of
NOTCH2 to 8 kb of intron 5 from 1p11 to 1q21.1, encoding the
truncated NOTCH2 N-terminal (N2N) gene [21]. Sequence compar-
ison between these duplicated regions revealed several single
nucleotide polymorphisms and microdeletions. We selected two
5-bp microdeletions from exons 1 and 4 of N2N to develop a PCR-
based assay, the ‘N2/N2N test’, that recognizes either genomic
region by size and determines its relative dosage in tumor DNA
(Figure 3A). Calculation of the ratio between NOTCH2 and N2N
PCR products levels in DNA from tumor and lymphocytes derived
from the same patient, evaluates the gene copy status at NOTCH2
relative to N2N. In 100% (21/21) of OG displaying 1p loss
(haplotype H10), this test showed imbalance between the
duplicated regions: exons 1 and 4 of NOTCH2 harbored half
copy number relative to N2N, indicating loss of one NOTCH2 copy
Table 1. Age of glioma patients at diagnosis.
..................................................................................................................................................
Histology Haplotype n= Median Survival* (months) Median Age* (years) Average Age6SD(years)
OD H1 5 13 [12–71] 50 [32–71] 51.6614.8
OD H10 21 98 [2–180] 49 [29–72] 50.6611.6
OD g 26 82.5 [2–180] 49.5 [29–72] 50.8611.9
GBM H1 80 12 [1–31] 61 [32–83] 58.7612.5
GBM H2–4 18 12.5 [5–28] 63.5 [26–80] 59.1614.9
GBM H5–7 11 5 [1–18] 54 [1–71] 50.7621.0
GBM H8–10 9 17 [6–45] 63 [36–74] 60.3611.1
GBM g 118 11 [1–45] 61 [1–83] 58.7612.5
*Extreme values are indicated between brackets
doi:10.1371/journal.pone.0000576.t001
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Table 2. Demographic and clinical data of GBM patients with
H8–H10 haplotypes.
......................................................................
Haplotype Patient Gender
Age
(years)
Survival
(months) Treatment
GBM H8 b138 M 57 45 S R
GBM H8 dG1 F 74 6 S R
GBM H8 dG40 F 63 29 S R C
GBM H9 b91 M 53 14 S R
GBM H9 b130 M 68 2* S
GBM H9 dG10 F 69 17 S R
GBM H10 b145 F 60 28 S R
GBM H10 b155 F 36 25 S R
GBM H10 dG53 M 63 14 S R C
*Death from pulmonary embolism
Treatments: radiotherapy (R), surgical resection (S), chemotherapy with
temozolomide (C)
doi:10.1371/journal.pone.0000576.t002
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PLoS ONE | www.plosone.org 3 June 2007 | Issue 6 | e576compared to N2N (OD 087, Figure 3B). Two OD cases with 1p loss
(AO80 and AO84) had fluorescence intensity of exon 4 of NOTCH2
close to baseline (Figure 3B). This indicated loss of both NOTCH2
genomic copies at this position and was confirmed by real-time
quantitative PCR to be a homozygous deletion. This genomic
imbalance showed that the breakpoints detected in OD with 1p loss
(Figures 1A and 3B) cluster between duplicated areas.
In contrast, 97% (35/36 cases with informative N2/N2N test) of
GBM with 1p loss (haplotypes H2–10) revealed equal copy
numbers with the N2/N2N test. Therefore, in GBM, breakpoints
on 1p are telomeric to the pericentric duplication, either towards
distal 1p, or 1q (Figure 3B). The single GBM showing an OD-like
pattern in the N2/N2N test (tumor 155, Figure 3C) was
histologically reclassified by two independent neuropathologists
as a GBM with oligodendroglial features. All analyzed GBM
without 1p loss (5/5) also had equal copy numbers between
NOTCH2 and N2N (tumor G49, Figure 3B). Hence, OD and
GBM display distinct 1p deletion patterns that can be recognized
by using the N2/N2N test. Moreover, results of the N2/N2N test
and fine mapping of centromeric deletions in GBM disclosed
a minimal area of loss located between the marker D1S514 and
exon 4 of NOTCH2, and homozygous deletions at exon 4 of
NOTCH2 in OD (Figure 3C). These findings render NOTCH2
a candidate tumor suppressor gene in all OD with 1p loss and in
the subgroup of GBM with centromeric 1p loss.
The centromeric 1p status is a predictor of glioma
patient survival
We performed receiver operating characteristics (ROC) analysis of
the different molecular markers with regard to prognosis (observed
survival). In addition, specificity and sensitivity at a cut-off of 24-
month were calculated for the 1p telomeric (D1S2845), interstitial
(D1S216), centromeric (D1S2696) and 19q (D19S589) micro-
satellite markers. With respect to microsatellite markers, D1S2696
was the most accurate 1p microsatellite marker to predict the
survival of glioma patients, with an area under curve (AUC) of
0.860 (Figure 4). However, the N2/N2N test predicted a 24-
month survival even more accurate, thus, with an exceptionally
high accuracy for a biological test (AUC=0.931). The information
content with respect to prognosis of the N2/N2N test was even
higher than the histological examination (AUC=0.891, Figure 4).
NOTCH2 status is a predictor of glioma patient
survival
Presently, estimation of glioma patient survival is based on
molecular diagnoses that identify OD with 1p loss, frequently
performed with telomeric 1p and 19q markers. We therefore
analyzed how the predictive power of either telomeric D1S2845 or
centromeric D1S2696 1p markers in combination with 19q status
relates to survival. In addition, survival time cut-off values which
Figure 2. Added value of chromosomes 1p and 19q molecular markers on glioma patient survival. D1S2696 is the best chromosome 1p
discriminator for better survival of GBM patients.
doi:10.1371/journal.pone.0000576.g002
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PLoS ONE | www.plosone.org 4 June 2007 | Issue 6 | e576Figure 3. Refinedsomatic1p deletion mappingin OD and GBM convergetothe NOTCH2 gene. (A) Schematic drawingof thechromosome 1 pericentric
duplication and principle of the PCR-based N2/N2Ntest.NOTCH2 markers are in black andN2N markersare in grey.(B) The N2/N2Ntest distinguishes GBM
(left) from OD (right). Electrophoretograms of GBM with (G10 and 091) or without (G49) 1p loss always show N2/N2N balance while OD have reduced
NOTCH2 copy number relative to N2N.I nG B M ,NOTCH2 and N2N copy numbers indicated underneath are deduced from allelic retention(G10) or loss(091)
atmarker210WF10.AO80andAO84aretworecentODwith1p/19qlossnotincludedintheinitialstatistics.(C)Refinedsomaticdeletionmappingdeduced
fromthe N2/N2N test.Chromosomal positions ofmarkers and pericentric duplication areshownon the left. InGBM, minimally lost area is distally delimited
by marker D1S514 (GBM G40 and G01) and proximally by NOTCH2 exon 4 (GBM G10). In OD, the minimal centromeric boundary of 1p loss is given by
NOTCH2 exon 1 (all OD), while 2 homozygous losses target Notch2 exon 4 (ODAO80 andAO84).Conventional LOHdataareshownby circles, datafrom the
N2/N2N test are shown by squares. White: retention of both alleles; black:loss of heterozygosity; black on a black background: homozygous loss; grey: non
informative. Areas of minimal allelic loss, highlighted in grey, are aligned with the targeted gene NOTCH2 shown with its sense of transcription.
doi:10.1371/journal.pone.0000576.g003
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PLoS ONE | www.plosone.org 5 June 2007 | Issue 6 | e576were calculated for 24, 36 and 48 months, were optimized for
discrimination of prognostic accuracy (Table 3). The N2/N2N test
and the histological classification (i.e. OD vs. GBM) were used for
stratification to determine the negative and positive predictive
values. The accuracy to predict survival of the centromeric 1p
marker D1S2696 together with the 19q status (0.800) were slightly
higher when compared to the combined use of telomeric D1S2845
and 19q status (0.762). However, using the centromeric marker
D1S2696 in combination with the N2/N2N test, the accuracy to
predict survival (more or less than 24 months) was 0.925, which
Figure 4. The N2/N2N test provides the highest accuracy to predict glioma patient survival. Receiver Operating Characteristics (ROC) curves
indicating the specificities (or 1-specificities, respectively) and the corresponding sensitivities at continuously varying cut-off points for survival time.
Thus, a given cut-off (particular survival time), the test result was determined for all individual tests (based on either molecular markers D19S589,
D1S2845, D1S216, D1S2696, N2/N2N, or histology) as being true or false positive, or true or false negative, respectively. Based on these data, the
specificities (or 1-specificities, respectively) and sensitivities calculated for each of the cut-off points.
doi:10.1371/journal.pone.0000576.g004
Table 3. Receiver operating characteristics for molecular markers D1S2696 and the N2/N2N-assay and tumor classification with
variable cut-off values.
..................................................................................................................................................
Predictive Value Marker Combinations
Cut-offs Survival
(months)
D1S2845+D19S589 D1S2696+D19S589 D1S2696+N2/N2N D1S2696+Histology
Negative 0.537 0.524 0.913 0.714 24
Negative 0.439 0.452 0.967 0.983 36
Negative 0.415 0.405 0.992 1 48
Positive 0.762 0.8 0.925 0.954 24
Positive 0.857 0.9 0.783 0.769 36
Positive 0.952 0.95 0.739 0.692 48
doi:10.1371/journal.pone.0000576.t003
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PLoS ONE | www.plosone.org 6 June 2007 | Issue 6 | e576was similar to the accuracy to predict survival of the histological
classification combined with the D1S2696 status (0.954, Table 3).
Thus, the combined use of molecular markers D1S2696 and
N2/N2N accurately predicts glioma survival by identifying
subgroups of OD and GBM with a better prognosis of survival,
and among them, by distinguishing OD from GBM.
DISCUSSION
We found that NOTCH2 is a common deletion target in OD as
well as in GBM, raising the hypothesis of a possible causal relation-
ship between NOTCH2 status and tumor behavior. NOTCH2
location near the chromosome 1 breakpoint cluster area of OD
with 1p/19q loss (Fig. 3B) suggests that NOTCH2 inactivation is
associated with the recently described OD translocation
t(1;19)(q10;p10) [9,10]. In GBM, although additional prognostic
factors would certainly had provided stronger validation, the low
number of tumors with 1p centromeric loss detected (n=9)
resulting from a low frequency event (8%), was sufficient to reach
high statistical significance (P=0.0175).
NOTCH signaling represents an evolutionarily conserved
pathway that controls key steps of development, cell growth and
differentiation [22]. During brain development, NOTCH2 is
expressed in the external granule layer of the cerebellum and in
postnatal brain, in dividing immature glial cells of ventricular
germinal zones [23,24]. NOTCH1 and NOTCH2 are involved in
neoplastic disease [25], e.g. leukemia [26,27], skin cancers [28], in
human medulloblastomas [29]. In fact, since NOTCH1 can be
regarded either as an oncogene or as a tumor suppressor, depend-
ingonthecellularcontext[25],this rulemayalsoapplytoNOTCH2.
Interestingly, a subset of GBM with better outcome shows expression
alterations in components of NOTCH pathway [30].
In a recent report, the existence of a deletion hotspot of
centromeric 1p in glioma has consistently been shown by com-
parative genomic hybridization [15]. ROC analysis with regard to
a 24-month survival first showed a higher relevance of centromeric
marker D1S2696 (AUC=0.860) compared to telomeric or 19q
markers. Moreover, the N2/N2N test predicted a 24-month
survival with high accuracy for a biological test (AUC=0.931),
even higher than the histological examination (AUC=0.891,
Figure 4). In fact, while marker D1S2696 defined all glioma, GBM
and OD, with 1p loss, and histology identified all OG regardless of
their genetic signature, the N2/N2N test allowed the distinction of
OG with 1p loss, precisely the subgroup of glioma with the best
outcome.
Identification of OD with 1p/19q loss is presently performed
with 1p telomeric and subtelomeric molecular markers in
combination with 19q markers. Our results show first that
diagnostic assessment of 1p telomeric markers cannot distinguish
between subgroups of prognostically better OD and poor GBM
with 1p deletions. Moreover, random distribution of 19q loss in
half of GBM with 1p loss did not resolve the complementary
assessment by the 19q status. As a consequence, numerous false
positive cases, particularly GBM with concomitant 1p and 19q loss
and poor survival lowered negative and positive predictive values
of combined telomeric 1p/19q marker data (0.762). In contrast,
when using the N2/N2N test, the GBM with poor survival could
be excluded in 21 out of 21 cases, thus, with a specificity of 100%
and a sensitivity of 97% (35 of 36 cases). Consistently, the accuracy
of the D1S2696-N2/N2N combined status to predict survival for
the 0.925 was similar to the D1S2696-histological classification
(0.954, Table 1).
We found that GBM with interstitial deletions located in the
1p22-32 interval had the poorest prognosis (Figure 1). They may
target one or more of the GBM suppressor genes linked with rapid
progression located between 1p32 and 1p22 (reviewed in [31].
Among them are RAD54 [6] and CDKN2C/p18
INK4c [14], both
located on 1p32. However, TP73 [13] and CHD5 [15], located on
1p36, are not included in this set of deletions. In contrast, GBM
with deletions at the 1p11-13 interval have a significantly better
prognosis than GBM with interstitial or telomeric deletion patterns,
and GBM without 1p loss (Figure 1). Those tumors display genetic
similarities to OD with 1p loss and may target a centromeric gene
located on 1p - and independently of 19q - that is linked with
a distinct prognostically better glioma pathway. A better patient
prognosis for OD with 1p/19q loss relative to other OD is
supported by the observation that among OD, 1p/19q loss and
TP53 mutations are mutually exclusive events, suggesting that OD
with either genetic alteration follow distinct tumor developmental
pathways [7]. Consistently, genetic profiling of primary OD
revealed that both genetic alterations are part of two distinct
molecular subgroups of OD [32]. In contrast, the interaction
shown between CHD5 and P53 in mouse fibroblasts [15] strongly
suggested that both proteins are part of the same cancer pathway.
In conclusion, we found the breakpoints of somatic deletions in
most OD and in a subgroup of GBM converging at the NOTCH2
gene locus which also harbors homozygous deletions in primary
OD. These findings raise the hypothesis of a role of NOTCH2 in
brain tumor development.
We further propose the combination of two NOTCH2 genetic
markers to provide sharp diagnostic and prognostic accuracy of
malignant gliomas.
MATERIALS AND METHODS
Patients
Frozen tissue samples of primary gliomas obtained from the
operating room and blood samples derived from the same patients
were processed as previously described [33], according to the
guidelines of the Ethical Committee of the University Hospitals of
Basel and Du ¨sseldorf, approved by all patients. Tumors were
diagnosed and graded according to the WHO Classification of
Tumors of the Nervous System [34]. Our series comprised 144
gliomas, including 16 OD WHO grade II, 10 anaplastic OD
WHO grade III and 118 GBM WHO grade IV. All patients
received open tumor resection, grade III and IV tumors external
beam radiotherapy.
Nucleic acid extraction and somatic deletion
mapping
Extraction of genomic DNA from biopsies and peripheral blood
mononuclear cells and LOH were performed as previously
described [33]. Microsatellite markers used [35] are: D1S468,
D1S2845, D1S244, D1S2667, D1S2740, D1S489, D1S228,
D1S507, D1S436, D1S2644, D1S482, D1S234, D1S470,
D1S2830, D1S2748, D1S2700, D1S438, D1S216, D1S207,
D1S2779, D1S495, D1S248, D1S2651, D1S502, D1S2881,
D1S252, D1S514, D1S2696, 210WF10, D1S2344, D1S442,
D1S2612, D1S498, D1S2343, D1S2635, D1S2878, D1S2691,
D1S238, D1S2757, D1S2655, D1S245, D1S2860, D1S251,
D19S589.
N2/N2N test
Genomic copy status was measured by taking advantage of
sequence polymorphisms between exons (Ex) 1 and 4 of the
NOTCH2 (N2) gene and its pericentric duplication N2N [18].
N2Ex1 primers (FAM)-gtgtcggcaaagccttcttt and ccctgttgtgaacttca-
cac generated fragments of 185bp (N2N) and 190bp (N2). N2Ex4
NOTCH2 Is a Survival Marker
PLoS ONE | www.plosone.org 7 June 2007 | Issue 6 | e576primers (TET)-cacagcacttatcacggtga and cccttcatatctccctactg gen-
erated fragments of 290bp (N2N) and 295bp (N2). PCR product
size fractionation and quantification were performed on ABI
Prism 310 Genetic Analyzer (PE Applied Biosystems, Foster,
USA). For each marker, NOTCH2 genomic status relative to N2N
was calculated as follows: for each marker, the ratio between peak
heights of NOTCH2 and N2N from tumor DNA [T(N2/N2N)] was
divided by that from autologous lymphocyte DNA [L(N2/N2N)].
Cut-offs for N2/N2N equimolarity, NOTCH2 single copy loss
relative to N2N were defined as follows: N2Ex1. 2n: 1.0060.13;
1n: 0.7460.13. N2Ex4. 2n: 1.0060.13; 1n: 0.5960.13. Potential
NOTCH2 homozygous deletions at exon 4 (N2Ex4,0.46) in AO80
and in AO84 were confirmed by real-time quantitative PCR
relative to GAPDH.
Statistical analysis
Histological and molecular genetic parameters potentially associ-
ated with survival time were determined. Factor analysis
(orthotran/varimax transformation method) was used to identify
highly correlated continuous parameters and to define the factors
to be subjected to the subsequent multivariate analysis of variance
(MANOVA). MANOVA was used for direct multivariate
comparison of the effects of the different histological and
molecular genetic factors on survival time, respectively, and to
determine the significance levels of these correlations. ANOVA
and post hoc tests were used for univariate comparison.
MANOVA, ANOVA, Kaplan-Meier curves including Logrank
Mantel-Cox comparison and significance levels of non-parametric
differences were computed using jmp, version 6.0 (SAS Institute
Inc., Cary, NC, USA). Receiver Operating Characteristic (ROC)
analyses were carried out with ROC, version 1.1 (diagene inc.,
Reinach, Switzerland) and jmp, version 6.0 (SAS Institute).
Sensitivity, specificity and predictive values calculations were
computed. All other calculations were performed using SPSS 9.0
(SPSS Inc., Chicago, IL, USA). Results are presented as means
(6SEM).
SUPPORTING INFORMATION
Figure S1 Kaplan Meier cumulative survival curve of OD
Haplotype H10 compared to OD Haplotype H1 and GBM
Haplotype H1.
Found at: doi:10.1371/journal.pone.0000576.s001 (0.57 MB TIF)
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